Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates Vascular 18F-FDG Uptake in Atherosclerotic Mice

: Mia Ståhle, Johanna M.U. Silvola, Sanna Hellberg, Margreet de Vries, Paul H. A. Quax, Jeffrey Kroon, Petteri Rinne, Alwin de Jong, Heidi Liljenbäck, Nina Savisto, Anna Wickman, Erik S.G. Stroes, Seppo Ylä-Herttuala, Pekka Saukko, Tommy Abrahamsson, Knut Pettersson, Juhani Knuuti, Anne Roivainen, Antti Saraste,

Publisher: Elsevier Inc

: 2020

: JACC: Basic to Translational Science

: 5

: 4

: 360

: 373

: 2452-302X

DOI: https://doi.org/10.1016/j.jacbts.2020.01.008

: https://research.utu.fi/converis/portal/detail/Publication/47290852

This study showed that treatment with a therapeutic monoclonal immunoglobulin-G1 antibody against phosphorylcholine on oxidized phospholipids preserves coronary flow reserve and attenuates atherosclerotic inflammation as determined by the uptake of 18F-fluorodeoxyglucose in atherosclerotic mice. The noninvasive imaging techniques represent translational tools to assess the efficacy of phosphorylcholine-targeted therapy on coronary artery function and atherosclerosis in clinical studies.

1-s2.0-S2452302X20300206-main.pdf